{"id":910357,"date":"2025-11-14T16:56:19","date_gmt":"2025-11-14T21:56:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/"},"modified":"2025-11-14T16:56:19","modified_gmt":"2025-11-14T21:56:19","slug":"enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/","title":{"rendered":"Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistcircle { list-style-type: circle }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results<\/b><\/p>\n<p class=\"bwalignc\"><i>In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional positive data in a preclinical model of PTSD, successful completion of dose range finding studies, and receipt of FDA response to pre-IND meeting request.<\/i><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nEnveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the third quarter ended September 30, 2025, and provided a comprehensive business update.<\/p>\n<p><b>CEO Commentary:<\/b><\/p>\n<p>\n\u201cThe third quarter of 2025 marked another highly productive period as we continue to advance our lead candidate EB-003 towards clinical trials in 2026,\u201d said Joseph Tucker, Ph.D., Director and CEO of Enveric. \u201cImportantly, we recently received a written response from the U.S. Food and Drug Administration (FDA) to our request for a Pre-Investigational New Drug (pre-IND) Type B meeting for EB-003, which we believe is consistent with our view that the preparations are sufficiently advanced to proceed to IND submission. Driving towards this significant inflection point, we also completed key chemistry, manufacturing, and controls (CMC) milestones, as well as dose range studies that helped to establish a maximum tolerated dose of EB-003.\u201d<\/p>\n<p>\n\u201cIn addition, our team continued to strengthen the profile of EB-003 across several neuropsychiatric indications, as we showed positive effects in a preclinical model of post-traumatic stress disorder (PTSD). Our research showed significantly decreased context-induced freezing behavior one-hour post-dose (p &lt; 0.05) indicating a positive therapeutic effect in a well-established translational rodent model for PTSD.\u201d<\/p>\n<p>\nDr. Tucker continued, \u201cIntellectual property remains a cornerstone of Enveric\u2019s value proposition, and during the third quarter we pursued opportunities to expand and defend our patent estate. Notably, we announced plans to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric\u2019s issued U.S. Patent No. 12,138,276 entitled, \u2018Halogenated Psilocybin Derivatives and Methods of Using.\u2019 The IP in question concerns claims that may be relevant to the Bretisilocin molecule, which was recently acquired by AbbVie in $1.2 billion deal.\u201d<\/p>\n<p>\n\u201cAs we approach 2026, we are excited to be working towards a streamlined IND application for EB-003 in preparation of a first-in-human study. We believe EB-003 has the potential to uniquely address mental health disorders, where innovation has been lacking for decades, with its dual mechanism of action that potentially engages both 5-HT<sub>2A<\/sub> and 5-HT<sub>1B<\/sub> receptors. In addition to being designed to promote neuroplasticity without hallucinogenic effects, we are optimistic that the dual mechanism represents a potentially first-in-class therapeutic target with significant clinical opportunity.\u201d<\/p>\n<p><b>Third Quarter and Recent Corporate Highlights<\/b><\/p>\n<p><b>Preclinical Development, Manufacturing and Regulatory Progress<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nSuccessfully completed pre-IND dose range finding studies for EB-003, establishing a maximum tolerated dose and supporting progression toward IND-enabling studies and first-in-human clinical trials<\/p>\n<\/li>\n<li>\nDemonstrated positive effects in preclinical model of PTSD, showing significantly decreased context-induced freezing behavior one-hour post-dose (p &lt; 0.05) and indicating a positive therapeutic effect in a well-established translational rodent model<\/p>\n<\/li>\n<li>\nSuccessfully completed key CMC milestones including:<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nIdentification and production of pharmaceutically compatible salt form designed to potentially improve drug effectiveness and stability<\/p>\n<\/li>\n<li>\nDevelopment and implementation of a scalable, reproducible synthetic process suitable for both current and future manufacturing of EB-003<\/p>\n<\/li>\n<li>\nSuccessfully produced a 1-kilogram batch of EB-003 as a pharmaceutically compatible salt to support IND enabling activities, including GLP toxicology studies and drug product formulation work<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\nContinued plans for EB-003 IND submission in 2026, after receiving the FDA response to the pre-IND package and meeting request.<\/p>\n<\/li>\n<\/ul>\n<p><b>Intellectual Property Activities<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nHired Fish and Richardson P.C. to defend U.S. Patent No. 12,138,276 with claims relevant to Bretisilocin, recently acquired by AbbVie in $1.2 billion deal<\/p>\n<\/li>\n<li>\nIssued a U.S. Patent, broadening the patent coverage for aminated psilocybin derivatives in the EVM-301 Series<\/p>\n<\/li>\n<li>\nIssued two U.S. Patents and received a U.S. Patent Allowance for potential next-generation, non-hallucinogenic mescaline derivatives in EVM401 Series<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nPatent-protected methylone-inspired analogs support pipeline expansion<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><b>Publications<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nAnnounced publication of two peer-reviewed articles highlighting novel bioproduction methods for neuropsychiatric drug discovery. Research published in <i>ACS Chemical Biology<\/i> and <i>BioDesign Research<\/i> describes new approaches for producing tryptamine and MDMA-derived compounds<\/p>\n<\/li>\n<\/ul>\n<p><b>Corporate\/Operational<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nRelocated corporate headquarters to Cambridge, MA aligning with Company\u2019s vision to leverage the Greater Boston biotech hub\u2019s scientific and financial ecosystem and advance EB-003 into first-in-human trial in 2026<\/p>\n<\/li>\n<li>\nAnnounced the closing of an exercise of certain outstanding series A warrants to purchase up to an aggregate of 101,042 shares of common stock of the Company and series B warrants to purchase up to an aggregate of 101,042 shares of common stock originally issued in February 2025, having an exercise price of $36.00 per share, at a reduced exercise price of $10.98 per share, adjusted for the reverse stock split. Gross proceeds to the Company from the exercise of the warrants were approximately $2.2 million, prior to deducting placement agent fees and estimated offering expenses<\/p>\n<\/li>\n<li>\nAfter the end of the Third Quarter of 2025, the Company completed a reverse stock split of its common stock on October 28, 2025, at a ratio of 1 post-split share for every 12 pre-split shares. The Board determined the reverse split was in the best interest of the shareholders after receiving conditional approval at the Company\u2019s annual meeting of stockholders on May 29, 2025 for an amendment to the Company\u2019s Amended and Restated Certificate of Incorporation to effect a reverse stock if the Company were to receive a delisting determination from Nasdaq for failure to maintain the required minimum bid price. The Company received a bid price deficiency delisting determination from Nasdaq on October 22, 2025.<\/p>\n<\/li>\n<\/ul>\n<p><b>Third Quarter 2025 Financial Results<\/b><\/p>\n<p>\nNet loss attributable to common stockholders was $3.4 million for the quarter ending September 30, 2025, or $10.81 per share, compared to a net loss of $2.1 million, or $43.10 per share, for the same period in 2024, adjusted for the reverse stock split. The net loss for the quarter included approximately $0.2 million in non-cash expenses related to stock-based compensation and other non-cash charges. As of September 30, 2025, Enveric had cash and cash equivalents of $3.8 million. The Company continues to fund its operations through the use of various financing tools. The Company has raised net proceeds of $7.9 million for the nine months ended September 30, 2025.<\/p>\n<p><b>About Enveric Biosciences<\/b><\/p>\n<p>\nEnveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric\u2019s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT<sub>2A<\/sub> and 5-HT<sub>1B<\/sub> receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.<\/p>\n<p>\nFor more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enveric.com&amp;esheet=54357883&amp;newsitemid=20251113113066&amp;lan=en-US&amp;anchor=www.enveric.com&amp;index=1&amp;md5=58f6c7dcdeb2f71e57a4f25cf99ae104\">www.enveric.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as \u201cplans,\u201d \u201cexpects\u201d or \u201cdoes not expect,\u201d \u201cproposes,\u201d \u201cbudgets,\u201d \u201cexplores,\u201d \u201cschedules,\u201d \u201cseeks,\u201d \u201cestimates,\u201d \u201cforecasts,\u201d \u201cintends,\u201d \u201canticipates\u201d or \u201cdoes not anticipate,\u201d or \u201cbelieves,\u201d or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: remain listed on Nasdaq, finalize and submit its IND filing to the U.S. Food and Drug Administration in 2026; achieve the value creation contemplated by technical developments; advance EB-003 toward clinical trials by 2026; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric\u2019s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.<\/p>\n<p>\nA discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric\u2019s filings with the Securities and Exchange Commission, including Enveric\u2019s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251113113066r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20251113113066\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20251113113066\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftiberend.com%2F&amp;esheet=54357883&amp;newsitemid=20251113113066&amp;lan=en-US&amp;anchor=Tiberend+Strategic+Advisors%2C+Inc.&amp;index=2&amp;md5=f354a72b3e701fb58c605f19848a3416\">Tiberend Strategic Advisors, Inc.<br \/>\n<\/a><br \/>David Irish<br \/>\n<br \/>(231) 632-0002<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:dirish@tiberend.com\">dirish@tiberend.com<\/a><\/p>\n<p><b>Media Relations<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftiberend.com%2F&amp;esheet=54357883&amp;newsitemid=20251113113066&amp;lan=en-US&amp;anchor=Tiberend+Strategic+Advisors%2C+Inc.&amp;index=3&amp;md5=3d5eb63e4bb635a481337860a0c0fb06\">Tiberend Strategic Advisors, Inc.<br \/>\n<\/a><br \/>Casey McDonald<br \/>\n<br \/>(646) 577-8520<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:cmcdonald@tiberend.com\">cmcdonald@tiberend.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology General Health Health Mental Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251113113066\/en\/2643678\/3\/Enveric.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional positive data in a preclinical model of PTSD, successful completion of dose range finding studies, and receipt of FDA response to pre-IND meeting request. CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the third quarter ended September 30, 2025, and provided a comprehensive business update. CEO Commentary: \u201cThe third quarter of 2025 marked another highly productive period as we continue to advance our lead candidate EB-003 towards clinical trials in 2026,\u201d said &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-910357","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional positive data in a preclinical model of PTSD, successful completion of dose range finding studies, and receipt of FDA response to pre-IND meeting request. CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the third quarter ended September 30, 2025, and provided a comprehensive business update. CEO Commentary: \u201cThe third quarter of 2025 marked another highly productive period as we continue to advance our lead candidate EB-003 towards clinical trials in 2026,\u201d said &hellip; Continue reading &quot;Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-14T21:56:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251113113066r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results\",\"datePublished\":\"2025-11-14T21:56:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\\\/\"},\"wordCount\":1565,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251113113066r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\\\/\",\"name\":\"Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251113113066r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-11-14T21:56:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251113113066r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251113113066r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/","og_locale":"en_US","og_type":"article","og_title":"Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results - Market Newsdesk","og_description":"Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional positive data in a preclinical model of PTSD, successful completion of dose range finding studies, and receipt of FDA response to pre-IND meeting request. CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the third quarter ended September 30, 2025, and provided a comprehensive business update. CEO Commentary: \u201cThe third quarter of 2025 marked another highly productive period as we continue to advance our lead candidate EB-003 towards clinical trials in 2026,\u201d said &hellip; Continue reading \"Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-14T21:56:19+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251113113066r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results","datePublished":"2025-11-14T21:56:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/"},"wordCount":1565,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251113113066r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/","name":"Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251113113066r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-11-14T21:56:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251113113066r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251113113066r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=910357"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910357\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=910357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=910357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=910357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}